<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03978364</url>
  </required_header>
  <id_info>
    <org_study_id>ShandongPH004</org_study_id>
    <nct_id>NCT03978364</nct_id>
  </id_info>
  <brief_title>A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC</brief_title>
  <official_title>An Randomized Controlled Study of Azacitidine Combined With Homoharringtonine Compared With Azacitidine for Patients With Int/High -Risk MDS and AML-MRC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Provincial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      evaluate the clinical efficacy and safety of azacitidine combined with HAG regimen for&#xD;
      patients with int/high -risk MDS and AML-MRC with less than 30% blasts compared with&#xD;
      azacitidine&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myelodysplastic syndromes (MDS) is a group of heterogeneous clonal diseases originating from&#xD;
      hematopoietic stem cells. The most common types of acute myeloid leukemia (AML) are AML with&#xD;
      myelodysplasia-related changes (AML-MRC) and AML-NOS. AML-MRC patients are usually with&#xD;
      multilineage pathological hematopoiesis, previous history of MDS or MDS-related cytogenetic&#xD;
      abnormalities. Compared with AML-NOS, AML-MRC patients are usually older, with poor prognosis&#xD;
      of cytogenetic changes, low remission rate of chemotherapy, and worse overall prognosis. The&#xD;
      treatment strategies mainly include demethylation drugs, chemotherapy and allogeneic&#xD;
      hematopoietic stem cell transplantation. The main purpose of treatment is to delay disease&#xD;
      progression, prolong survival, and even be cured.&#xD;
&#xD;
      Epigenetic changes such as DNA methylation and histone deacetylation have been considered to&#xD;
      be involved in the occurrence and development of MDS. Demethylation drugs, such as&#xD;
      5-azacitidine (AZA) and 5-aza-2-deoxycytidine (decitabine), can inhibit DNA&#xD;
      methyltransferase, reduce excessive methylation of tumor suppressor genes, promote cell&#xD;
      differentiation and apoptosis, and play an anti-tumor role. Demethylation drugs are important&#xD;
      therapy for MDS patients. Compared with supportive treatment, demethylation drugs can reduce&#xD;
      the risk of AML progression and improve survival.&#xD;
&#xD;
      Therefore, we proposed this project in order to further clarify the role of azacytidine in&#xD;
      therapy for high-risk and middle-risk MDS and AML-MRC patients, and evaluate its clinical&#xD;
      efficacy, to explore the optimal azacytidine treatment strategies for high-risk and&#xD;
      middle-risk MDS and AML-MRC patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Myelodysplastic Syndromes,Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>azacitidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>azacitidine&#xD;
azacitidine 75mg/m2，iH，qd， d1-7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>azacitidine combined HHT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>azacitidine+HHT azacitidine 75mg/m2，iH，qd， d1-7 HHT 3mg/m2,ivdrip qd,d1-3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine combined HHT</intervention_name>
    <description>Azacitidine 75mg/m2，iH，qd×7days，HHT，3mg/m2 ivdrip qd×3 days</description>
    <arm_group_label>azacitidine combined HHT</arm_group_label>
    <other_name>Azacitidine+HHT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine regimen</intervention_name>
    <description>Azacitidine 75mg/m2，iH，qd×7days，28 days a cycle</description>
    <arm_group_label>azacitidine</arm_group_label>
    <other_name>Azacitidine group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged between 18-75 years old, male or female;&#xD;
&#xD;
          2. Int/high risk MDS AND AML patients (non-AML-M3) diagnosed according to the 2008 World&#xD;
             Health Organization (WHO) diagnosis of myeloid malignant disease;&#xD;
&#xD;
          3. The ECOG behavior status score is 0-3 points;&#xD;
&#xD;
          4. The expected survival time is ≥ 3 months;&#xD;
&#xD;
          5. Ability to understand and be willing to sign the informed consent form of this trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. In the past, allergy to the drug contained in the test protocol or to a drug similar&#xD;
             to the chemical structure of the test drug;&#xD;
&#xD;
          2. There are serious active infections;&#xD;
&#xD;
          3. Patients with clinically significant QTc interval prolongation (male &gt; 450ms, female &gt;&#xD;
             470ms), ventricular tachycardia (VT), atrial fibrillation (AF), grade II or higher&#xD;
             heart block, myocardial infarction (MI) Patients with coronary heart disease who have&#xD;
             congestive heart failure (CHF) within 1 year and who are symptomatic for medical&#xD;
             treatment;&#xD;
&#xD;
          4. Heart B-ultrasound shows patients with end-diastolic pericardial cavity dark area&#xD;
             width ≥ 10mm;&#xD;
&#xD;
          5. Patients with active bleeding;&#xD;
&#xD;
          6. Patients with new diseases such as thrombosis, embolism and cerebral hemorrhage in the&#xD;
             past six months;&#xD;
&#xD;
          7. Abnormal liver function (total bilirubin &gt; 1.5 times the upper limit of normal value,&#xD;
             2.5 times the upper limit of ALT / AST &gt; normal value or 5 times the upper limit of&#xD;
             ALT / AST &gt; normal value in patients with liver invasion), abnormal renal function&#xD;
             (serum Creatinine &gt; 1.5 times the upper limit of normal);&#xD;
&#xD;
          8. The investigator determined that it was not suitable for the participants.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hematology, Shandong Provincial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin Wang, MD, PhD</last_name>
    <phone>86-531-68778331</phone>
    <email>xinw@sdu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shandong Provincial Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Wang, MD, PHD</last_name>
      <phone>86-531-68778331</phone>
      <email>xinw@sdu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xiaohui Sui, MD</last_name>
      <phone>86-531-68778331</phone>
      <email>suzysui@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Provincial Hospital</investigator_affiliation>
    <investigator_full_name>Wang Xin</investigator_full_name>
    <investigator_title>director of hematology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

